EuroPCR’23: BIOADAPTOR RCT results comparing novel DynamX Bioadaptor to Resolute Onyx DES
Published: 22 June 2023
Elixir Medical has announced positive results from the BIOADAPTOR RCT trial, comparing DynamX Bioadaptor to Resolute Onyx DES. The trial met its primary endpoint of TLF non-inferiority at 12 months. The bioadaptor demonstrated a TLF rate of 1.8% compared to 2.8% for the stent (p<0.001) and showed improved vessel function and pulsatility. Principal investigators Dr Shigeru Saito (Shonan Kamakura General Hospital - Kamakura, JP) and Dr Stefan Verheye (ZNA Middelheim - Antwerp, BE) highlighted the bioadaptor's ability to free the vessel, establishing a new standard of effectiveness. These findings also suggest potential benefits in plaque changes. The results were presented at EuroPCR 2023.
More from this programme
Director of Cardiology and Catheterisation Laboratories
Dr Shigeru Saito is the Director of Cardiology and Catheterisation Laboratories, at Shonan Kamakura General Hospital in Kamakura, Japan. Dr Saito is one of the leading supporters and practitioners of transradial coronary intervention (TRI) in the world. As an evangelist for TRI, he has travelled the world to teach and demonstrate the benefits and techniques of this alternative to the femoral approach.
One of Dr Saito’s primary activities is to develop a strategy of retrograde approach in coronary angioplasty for chronic total occlusion. He serves as President of NPO International TRI Network. He serves on the editorial boards of Catheterization and Cardiovascular Interventions, Journal of Invasive Cardiology and the International Journal of Cardiology. Dr Saito is widely published in the fields of acute myocardial infarction, cardiomyopathy, coronary angioplasty and the transradial approach.
Dr Stefan Verheye, is a senior interventional cardiologist at the Antwerp Cardiovascular Center, Antwerp Belgium since 2000. He is a member of the European Association of Percutaneous Cardiovascular Interventions, a member of the Belgian Working Group on Interventional Cardiology, and has been appointed as Clinical Professor Interventional Cardiology at the University of Brussels. He serves as a member of Scientific Advisory Board of several medical device manufacturers. Dr Verheye is the author of over 150 peer-reviewed journals, ten book chapters, over 400 abstracts, serves on the editorial board of the European Heart Journal – Digital Health and has led (as global principal investigator) and participated in numerous clinical (Phase I and II) and pre-clinical research studies in the field of innovative interventional cardiology (coronary artery disease, structural heart disease, heart failure).